Table 4.

Risk of PCSM by SLCO2B1 and SLCO1B3 SNP genotypes in a population-based prostate cancer cohorta

 SNPGenotypeProstate cancer deathHR (95% CI)c
NobYes
SLCO2B1rs12422149GG993 (95.6)46 (4.4)1.00 (referent)
GA + AA210 (92.5)17 (7.5)1.99 (1.11–3.55)
SLCO2B1rs949069GG811 (95.5)38 (4.5)1.00 (referent)
GA + AA397 (93.9)26 (6.2)1.39 (0.82–2.34)
SLCO2B1rs2712819AA777 (95.0)41 (5.0)1.00 (referent)
AG + GG431 (95.1)22 (4.9)1.02 (0.60–1.77)
SLCO2B1rs2851069CC452 (95.2)23 (4.8)1.00 (referent)
CT + TT752 (94.7)42 (5.3)1.21 (0.72–2.05)
SLCO2B1rs7947726GG999 (95.1)51 (4.9)1.00 (referent)
AG + AA204 (94.0)13 (6.0)0.75 (0.37–1.53)
SLCO1B3rs4149117GG885 (95.4)43 (4.6)1.00 (referent)
GT + TT326 (93.7)22 (6.3)1.76 (1.00–3.08)
SLCO1B3rs3829311GG812 (95.0)43 (5.0)1.00 (referent)
GA + AA396 (94.7)22 (5.3)1.28 (0.74–2.23)
SLCO1B3rs4762803CC958 (94.8)53 (5.2)1.00 (referent)
CG + GG251 (95.4)12 (4.6)1.16 (0.59–2.30)
  • aVariable number of cases due to failed genotyping.

  • bIncludes 115 men who died of nonprostate cancer causes and who were censored at time of death.

  • cAdjusted for age, PSA at diagnosis, Gleason score, stage, primary treatment, BMI, and smoking status.